Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Male of female gender~* Written informed consent provided by the patients or by a first-degree relative in case of patients unable to consent~* In case of women, unwillingness to remain pregnant during the study period achieved either by their partner using condom or by themselves using oral contraceptives.~* Confirmed infection by SARS-CoV-2 virus~* Infection of the upper respiratory tract or of the lower respiratory tract~Exclusion Criteria:~* Age below 18 years~* Denial of written informed consent~* Intake of any macrolide for the current episode of infection under study~* Intake of hydroxychloroquine or chloroquine phosphate.~* Presence of severe respiratory failure~* Oral or intravenous intake of corticosteroids defined as any more than 0.4mg/kg daily intake of equivalent prednisone for the last 15 days~* Neutropenia defined as an absolute neutrophil count below 1,000/mm3~* Presence of any contraindications for the study drugs as stated in local label information~* QTc interval at rest electrocardiogram ≥500 msec or history of known congenital long QT syndrome~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarithromycin arm (Type: EXPERIMENTAL): Treatment will last for seven days. Every patient will receive one tablet of 500 mg of clarithromycin every 12 hours. It is explicitly stated that all other treatment is allowed with the only exclusion the parallel intake of a) any other drug of the macrolide class of antibiotics; and/or b) hydroxychloroquine or chloroquine phosphate. Drugs contraindicated with the intake of clarithromycin are also not allowed, as they are described in the local label information.

Based on this trial design, predict the completion outcome and termination type (if applicable).